Neuroendocrine breast carcinomas (NBCs) account for 2-5% of all invasive breast cancers, and are histologically similar to neuroendocrine tumours from other sites. They typically express oestrogen receptor (ER), and are HER2-negative and of luminal 'intrinsic' subtype. Here, we sought to define the mutational profile of NBCs, and to investigate whether NBCs and common forms of luminal (ER + /HER2 − ) breast carcinoma show distinct repertoires of somatic mutations. Eighteen ER + /HER2 − NBCs, defined as harbouring >50% of tumour cells expressing chromogranin A and/or synaptophysin, and matched normal tissues were microdissected and subjected to massively parallel sequencing targeting all exons of 254 genes most frequently mutated in breast carcinomas and/or related to DNA repair. Their mutational repertoire was compared with that of ER + /HER2 − breast carcinomas (n = 240), PAM50-defined luminal breast carcinomas (luminal A, n = 209; luminal B, n = 111) and invasive lobular carcinomas (n = 127) from The Cancer Genome Atlas. NBCs were found to harbour a median of 4.5 (range 1-11) somatic mutations, similar to that of luminal B breast carcinomas (median = 3, range 0-17) but significantly higher than that of luminal A breast carcinomas (median = 3, range 0-18, p = 0.02). The most frequently mutated genes were GATA3, FOXA1, TBX3, and ARID1A (3/18, 17%), and PIK3CA, AKT1, and CDH1 (2/18, 11%). NBCs less frequently harboured PIK3CA mutations than common forms of ER + /HER2 − , luminal A and invasive lobular carcinomas (p < 0.05), and showed a significantly higher frequency of somatic mutations affecting ARID1A (17% versus 2%, p < 0.05) and the transcription factor-encoding genes FOXA1 (17% versus 2%, p = 0.01) and TBX3 (17% versus 3%, p < 0.05) than common-type ER + /HER2 − breast carcinomas. No TP53 somatic mutations were detected in NBCs. As compared with common forms of luminal breast carcinomas, NBCs show a distinctive repertoire of somatic mutations featuring lower frequencies of TP53 and PIK3CA mutations, enrichment for FOXA1 and TBX3 mutations, and, akin to neuroendocrine tumours from other sites, ARID1A mutations.
Introduction
Breast carcinomas with neuroendocrine differentiation [also known as neuroendocrine breast carcinomas (NBCs)] account for 2-5% of all invasive breast carcinomas. These tumours usually affect elderly women, and are defined by the World Health Organization (WHO) as invasive carcinomas showing morphological characteristics similar to those of neuroendocrine neoplasms of other organs, including the gut [1] . Tumour cells are typically arranged in solid nests and/or tra406 C Marchiò et al neuroendocrine markers. A pragmatic threshold of >50% of neuroendocrine marker expression in tumour cells has been suggested [2] , although the latest WHO classification has clarified that this cut-off was set arbitrarily [1] . Depending on the threshold and the particular immunohistochemical markers employed, the prevalence of neuroendocrine differentiation varies between 4% and 18% of breast cancers [3] [4] [5] [6] . Nevertheless, regardless of thresholds and markers for neuroendocrine differentiation, there is substantial inter-tumour histological heterogeneity within NBCs, as demonstrated by the fact that only a subgroup of breast carcinomas showing neuroendocrine differentiation as defined by immunohistochemistry harbour the typical neuroendocrine morphology [4, 5] . Indeed, NBCs may have features shown by non-neuroendocrine carcinomas, including apocrine differentiation [7] , or architectural features consistent with other histological special types, such as cellular mucinous carcinomas (i.e. type B) and solid papillary carcinomas [8] .
NBCs are typically oestrogen receptor (ER)-positive and HER2-negative, and are more frequently of luminal A than of luminal B 'intrinsic' subtype [9] . We have previously shown that neuroendocrine and mucinous carcinomas are transcriptionally distinct from invasive ductal carcinomas (IDCs) of no special type [also known as invasive carcinomas of no special type (IC-NSTs)], and that neuroendocrine and type B mucinous carcinomas have similar transcriptomic profiles [9] . Although NBCs are preferentially of luminal A subtype and may sometimes be classified as of other histological types with a favourable prognosis, a retrospective analysis has suggested that patients with NBCs have a worse prognosis than those with IC-NSTs [5, 10] , and may benefit less from endocrine therapy [10] . Therefore, the impact of neuroendocrine differentiation on the prognosis of breast cancer patients is uncertain. Furthermore, it remains to be determined whether neuroendocrine differentiation in breast carcinomas is associated with, or driven by, highly recurrent somatic genetic alterations or a distinctive repertoire of mutations.
Massively parallel sequencing (MPS) studies have revealed that breast carcinomas comprise a heterogeneous group, with only three genes being mutated in >10% of the tumours (i.e. TP53, PIK3CA, and GATA3) [11, 12] . The Cancer Genome Atlas (TCGA) study has revealed that, although luminal A and B, HER2-enriched and basal-like PAM50-defined molecular subtypes harbour distinct repertoires of somatic genetic alterations [12] , there is no highly recurrently mutated gene or highly recurrent mutation that defines each 'intrinsic' subtype [11] . It should be noted, however, that large-scale MPS endeavours have so far focused primarily on the most common types of breast carcinoma, i.e. IC-NSTs [12] [13] [14] [15] and invasive lobular carcinomas (ILCs) [16] .
The aims of this study were to investigate whether NBCs harbour mutations affecting the genes that are most frequently mutated in breast carcinomas, and whether these carcinomas have a repertoire of somatic mutations affecting the genes that are most frequently mutated in breast carcinomas and DNA repair-related genes that is distinct from that of common forms of luminal (ER + /HER2 − ) breast carcinoma.
Materials and methods

Cohort and immunohistochemistry
From the files of the Pathology Unit of Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, we selected 18 invasive breast carcinomas showing neuroendocrine differentiation, as defined by morphological features reminiscent of neuroendocrine differentiation and immunohistochemical expression of chromogranin A and/or synaptophysin in >50% of tumour cells [2] . Samples were anonymized prior to analysis. This study was approved by the Institutional Review Board (IRB) of the Department of Medical Sciences of the University of Turin. Patient consent was obtained where appropriate, according to the protocol approved by the IRB. Representative haematoxylin and eosin (H&E)-stained sections of each case were reviewed by four of the authors (C.M., F.C.G., A.S., and J.S.R.-F.), who performed a central review of the cases, with detailed analysis of their histological features, histological typing [8] , and histological grading [17] . As previously recommended [18] , NBCs were typed according to their main histological features according to the 2012 WHO classification [8] . For instance, NBCs fulfilling the criteria for a diagnosis of mucinous carcinoma were classified as NBC-mucinous carcinomas, whereas NBCs lacking the features of a recognized histological special type were classified as IDCs with neuroendocrine differentiation according to the latest WHO classification.
Immunohistochemical analysis of ER, progesterone receptor, HER2, Ki67, chromogranin A, synaptophysin and E-cadherin was performed as previously described [19] (Supplementary materials and methods  and Table S1 ).
Microdissection and DNA extraction
Eight-μm-thick sections from representative formalinfixed paraffin-embedded blocks of the tumour and normal breast tissue from each case were microdissected as previously described [20] to ensure >80% of tumour cell content and that the normal tissue was devoid of neoplastic cells (Supplementary materials and methods). Genomic DNA was extracted and quantified as previously described [21] (Supplementary materials and methods). Table S2 ), as previously described [20] . Sequencing analysis was performed essentially as reported in Piscuoglio et al [20] (Supplementary materials and methods), with state-of-the-art bioinformatics tools [21] [22] [23] .
Genetics of neuroendocrine breast cancer 407
The potential functional effect of each single nucleotide variation (SNV) was investigated with a combination of MutationTaster [24] and CHASM [25] , as previously reported [26] . Genes affected by mutations were further annotated according to their presence in three cancer gene datasets, i.e. Kandoth et al [27] , the Cancer Gene Census [28] , and Lawrence et al [29] . Sequencing data have been deposited in the NCBI Sequence Read Archive under accession code SRP071884.
Sanger sequencing
Selected somatic mutations, including putative recurrent mutations, were further validated by Sanger sequencing as previously described [21] (Supplementary materials and methods and Table S3 ). All analyses were performed in duplicate.
Comparisons with invasive breast carcinomas from the TCGA dataset
To compare the mutational frequencies of NBCs with those of ER + /HER2 − and PAM50-defined luminal A/B invasive breast carcinomas and with those of ILCs, we retrieved the clinicopathological data and whole-exome sequencing-derived mutational data from the TCGA data portal (accessed in May 2016), essentially as previously described [20] (Supplementary materials and methods). Specific subgroup analyses are described in the Supplementary materials and methods. Comparisons were performed by the use of two-tailed Fisher's exact tests, and the confidence intervals for the odds ratios were estimated with the minimum likelihood method [30] .
Identification of transcript-defined NBCs (TD-NBCs)
As an exploratory, hypothesis-generating analysis, we sought to define TD-NBCs on the basis of mRNA expression profiles, and to compare their characteristics with those of the NBCs included in this study and of ER + /HER2 − breast carcinomas from the TCGA study. Detailed methods for the centroid generation, classification of the TCGA samples, hierarchical cluster analysis, cluster robustness assessment and statistical analyses are described in the Supplementary materials and methods. 
Results
NBCs show heterogeneous histological features
As an inclusion criterion, all NBCs of the present study showed >50% of chromogranin A and/or synaptophysin expression (Table 1) . Chromogranin A was expressed in a granular pattern and, in some cases, in the form of paranuclear dots, whereas synaptophysin showed diffuse cytoplasmic expression of varying intensity ( Figure 1 ). The 15 carcinomas classified as IDCs with neuroendocrine differentiation showed heterogeneous histological features; however, as a group, these tumours showed clearly infiltrative, large rounded solid nests and/or trabeculae of cells immersed in a hyalinized stroma. Cells were often juxtaposed to delicate fibrovascular structures, reminiscent of solid papillary differentiation. Three of those 15 cases showed focal solid papillary formations, but did not fulfil the criteria to be classified as solid papillary carcinomas [8] . Of these cases, 11 (73%) were of nuclear grade 2, and, akin to neuroendocrine neoplasms of other sites, nuclei were homogeneous across the whole tumour. Three cases were classified as special histological types; of these cases, two were classified as grade 2 mucinous type B (hypercellular) carcinomas, and one as a grade 2 solid variant ILC with a minor signet ring cell component ( Table 1) . None of the NBCs analysed here showed histological features of small cell carcinoma.
Immunohistochemical analysis revealed that all cases showed a luminal-like phenotype [i.e. ER + /HER2 − (Table 1) ]. E-cadherin immunohistochemistry revealed complete lack of expression in the sole case diagnosed as an ILC. In addition, reduced and/or heterogeneous staining was observed in six of 18 cases (33% ;  Table 1 ; supplementary material, Figure S1 ). The remaining 11 cases showed strong, membranous expression of E-cadherin, similarly to the pattern 
Mutational repertoire of NBCs
Targeted capture MPS was performed at a median depth of 568× (448×-754×), and resulted in the identification of a median of 4.5 somatic mutations affecting the 254 genes tested (range 1-11). A reanalysis of the 240 ER + /HER2 − , 209 luminal A and 111 luminal B cases from the TCGA breast cancer study revealed a median of three somatic mutations (range 0-18 for ER + /HER2 − and luminal A; range 0-17 for luminal B) affecting the exons of the 254 genes included in our targeted panel [12] . A median of three somatic mutations was also found for ILCs (range 0-56). Although the frequency of somatic mutations was comparable between NBCs and ER + /HER2 − breast carcinomas, luminal B breast carcinomas and ILCs from TCGA, as also highlighted by the interquartile range and highest and lowest value of the number of mutations, excluding outliers ( Figure 2 ), there was a significantly higher number of somatic mutations affecting these 254 genes in NBCs than in the luminal A breast carcinomas from TCGA (p = 0.02, Mann-Whitney U-test; Figure 2 ). Although these differences may reflect the biology of NBCs, it is also plausible that they may stem from the fact that, in our study, cases were microdissected and the sequencing depth was substantially higher than that of breast carcinomas analysed by TCGA.
The most frequently mutated cancer genes in NBCs were GATA3, FOXA1, TBX3, and ARID1A (all mutated in three of 18 cases, 17%), followed by PIK3CA, AKT1, and CDH1 (all mutated in two of 18 cases, 11%; Figure 3 , supplementary material, Table S4 ). As expected, the lobular carcinoma (CMNE24T) was one of the two cases harbouring a CDH1 mutation; in this case, the E806K missense CDH1 mutation was coupled with loss of heterozygosity (LOH) of the wild-type allele and predicted to be clonal (i.e. present in 100% of the tumour cells). Immunohistochemical analysis also revealed lack of E-cadherin expression. The other case harbouring a CDH1 somatic mutation (CMNE22T) was classified as an IDC with neuroendocrine differentiation. A thorough review of this case failed to reveal any unequivocal areas consistent with an ILC, and confirmed membranous expression of E-cadherin. In this case, the R598Q missense CDH1 mutation was also coupled with LOH of the wild-type allele; however, it was predicted to be subclonal (present in 16% of cancer cells; supplementary material, Table S4 ), potentially explaining the lack of overt lobular differentiation. None of the NBCs analysed harboured TP53 somatic mutations. Sanger sequencing analysis of selected mutations resulted in a validation rate of 100% (26/26) , and confirmed the presence of the FOXA1, ARID1A, GATA3, CDH1, AKT1, PIK3CA, KIT, HUWE1, TBX3, KMT2C and SPEN somatic mutations (supplementary material, Figure S2 ).
When compared with immunohistochemically defined ER + /HER2 − breast carcinomas from TCGA (n = 240), NBCs less frequently harboured PIK3CA mutations than common-type ER + /HER2 − breast carcinomas (11% versus 42%, p = 0.01, Fisher's exact test; Table 2 ), and showed a significantly higher frequency of somatic mutations affecting the chromatin-remodelling gene ARID1A (17% versus 2%, p = 0.01, Fisher's exact test), akin to pulmonary carcinoids [31] , and the transcription factor-encoding genes FOXA1 and TBX3 (17% versus 2% and 17% versus 3%, p = 0.01 and p = 0.03, respectively, Fisher's exact tests). TP53 was significantly less frequently mutated in NBCs than in ER + /HER2 − breast carcinomas from TCGA (0% versus 22%, p = 0.01, Fisher's exact test).
As an exploratory, hypothesis-generating analysis, we compared the repertoires of somatic mutations found in NBCs with those of PAM50-defined luminal A (n = 209) and luminal B (n = 111) breast carcinomas from TCGA. NBCs showed a repertoire of somatic mutations that was intermediate between those of luminal A and luminal B breast carcinomas, with a significantly higher frequency of FOXA1, ARID1A and DCHS2 mutations in NBCs (all mutated in 17% of cases) than in both luminal A breast carcinomas (2%, 2%, and 1%, respectively, p < 0.05, Fisher's exact tests) and luminal B breast carcinomas (2%, 3%, and 2%, respectively, p < 0.05, Fisher's exact tests; Table 2 and Figure 4 ). In addition, PIK3CA mutations were significantly less frequent in NBCs (11%) than in luminal A breast carcinomas (46%, p < 0.01, Fisher's exact test), whereas none of the NBCs showed TP53 mutations, as compared with 32% of luminal B breast carcinomas (p < 0.01, Fisher's exact test) and 11% of luminal A breast carcinomas (p = 0.23, Fisher's exact test; Table 2 and Figure 4) . Conversely, TBX3 and Repertoire of non-synonymous somatic mutations in 18 NBCs. Heatmap illustrating the non-synonymous somatic mutations considered to be non-neutral/non-passenger by either MutationTaster [24] or CHASM (breast) [25] . Cases are represented in columns; genes are depicted in rows in decreasing order of mutational frequency. Mutation types are colour-coded according to the key. The presence of loss of heterozygosity (LOH) of the wild-type allele in association with the somatic mutation is depicted by a diagonal bar. Right: the membership of each gene in three cancer datasets (grey square, presence in respective dataset). IDC-NE, invasive ductal carcinoma with neuroendocrine differentiation; MBC, mucinous breast carcinoma.
HUWE1 were more frequently found to be mutated in NBCs (17% and 11%, respectively) than in luminal A breast carcinomas (2% and 1%, p < 0.05, Fisher's exact tests; Table 2 and Figure 4) .
Given that lobular and mucinous carcinomas have been shown to differ from IC-NSTs at the molecular level [9, 16, [32] [33] [34] , we sought to investigate whether IDCs with neuroendocrine differentiation constituted a more homogeneous group at the genetic level and harboured a different mutational landscape from that observed in unselected breast carcinomas. We therefore performed an exploratory comparative analysis of the set of 15 IDCs with neuroendocrine differentiation with ER + /HER2 − (n = 210) and PAM50-defined luminal A (n = 179) and luminal B (n = 105) breast carcinomas from TCGA, from which lobular, mucinous and neuroendocrine carcinomas were excluded (Table 3) . These subgroup analyses highlighted that FOXA1, TBX3 and DCHS2 were significantly more frequently mutated in IDCs with neuroendocrine differentiation than in any of the three subgroups from TCGA (all 20% in NBCs versus 2% in ER + /HER2 − and luminal A and 2%, 4% and 2% in luminal B breast carcinomas, respectively, p < 0.05, Fisher's exact tests). In addition, the lower frequencies of PIK3CA mutations (13% versus 42% in ER + /HER2 − breast carcinomas, p = 0.03, and 47% in luminal A breast carcinomas from TCGA, p = 0.01, Fisher's exact test) and the lack of TP53 mutations (0% versus 25% in ER + /HER2 − breast carcinomas, p = 0.02, and 33% in luminal B breast carcinomas, p < 0.01, Fisher's exact test) in IDCs with neuroendocrine differentiation remained statistically significant.
Given that some genes found to be recurrently mutated in NBCs, such as FOXA1 and TBX3, have been recently described as some of the molecular determinants of ILCs [16] , we endeavoured to assess whether similarities could be found between our cohort of NBCs and lobular carcinomas from TCGA in terms of mutations affecting the exons of the 254 genes included in the targeted panel employed in this study. In addition to the statistically significant higher frequency of CDH1 mutations in ILCs than in NBCs (63% versus 11%, p < 0.01, Fisher's exact test; Table 2 and Figure 4) , we observed that NBCs less frequently harboured PIK3CA mutations (11% versus 48%, p < 0.01, Fisher's exact test; Table 2 ) and more frequently harboured 
DCHS2, MACF1
and CTCF mutations (17%, 11%, and 11%, respectively) than ILCs (1%, 1%, and 0%, respectively, Fisher's exact tests; Table 2 and Figure 4 ). Overlapping results were obtained when the comparison was restricted to the 15 IDCs with neuroendocrine differentiation (Table 3) .
Patterns of gene copy number alterations in NBCs
NBCs harboured recurrent copy number alterations, including gains of 1q, 8q, 12q, 14p, and 16p, and losses of 1p, 6p, 11q, 14q, and 16q ( Figure 5 ). Concurrent 1q gains and 16q losses, which represent the hallmark genetic aberrations found in ≥75% of grade 1/2 luminal breast carcinomas [35] , were observed in five of 18 (28%) cases and in none of the mucinous carcinomas with neuroendocrine differentiation, in agreement with our previous findings [32, 36] . Amplifications affecting loci reported to be recurrently amplified in breast carcinomas were observed in NBCs, including 8p11.23-11.21 encompassing ZNF703, FGFR1, and POLB (two cases), 8q24.12 encompassing DEPTOR (three cases), and 8q24.3 encompassing PTK2, EPPK1, and PLEC (three cases; Table 4 ). In addition, FOXA1 and ERBB4 amplifications were found in one case each (Table 4) . No homozygous deletions were detected. A comparison of ER + /HER2 − NBCs and luminal A/B breast carcinomas from TCGA revealed that the only statistically significant differences were gains of 1q, 8q, 17q, and 20q, which were more frequently found in luminal B breast carcinomas from TCGA than in NBCs (p < 0.05, Fisher's exact tests; Figure 5 ). It is of note that, when the comparison was performed between IDCs with neuroendocrine differentiation and breast carcinomas from TCGA from which we excluded lobular, mucinous and neuroendocrine carcinomas, no significant differences were detected in terms of copy number changes between NBCs and any of the groups analysed (supplementary material, Figure S3 ).
Finally, the comparison between NBCs and ILCs from TCGA revealed that 1q gains and 16q losses were significantly more frequently found in ILCs than in NBCs (also after exclusion of mucinous and lobular carcinomas, p < 0.05, Fisher's exact tests; Figure 5 ; supplementary material, Figure S3 ). This is not surprising, given that these genetic alterations represent hallmark features of ILCs [16, 33] , and that we observed concurrent 1q gains and 16q losses only in 28% of NBCs, as reported above.
Unsupervised clustering analysis of NBCs and ER
+ /HER2 − breast carcinomas from the TCGA dataset
As an exploratory, hypothesis-generating analysis, we sought to define whether the genetic differences between NBCs and IC-NSTs identified in this study could be generalized in a larger dataset. We first employed a centroid derived from the reanalysis of the NBCs and mucinous carcinomas from Weigelt et al [9] , and used this centroid to identify the ER + /HER2 − breast carcinomas from the TCGA breast cancer study that showed neuroendocrine differentiation according to transcriptomic data (i.e. transcript-defined or TD-NBCs; see Supplementary materials and methods). Of the 241 ER + /HER2 − cases of the TCGA dataset, 53 (22%) were classified as TD-NBCs. An unsupervised clustering analysis based on the repertoire of somatic mutations of the NBCs included in this study and all ER + /HER2 − breast carcinomas from the TCGA study demonstrated that 17 of 18 (94%) NBCs of our cohort belonged to a single stable cluster ('NBC-enriched cluster'; Figure 6 ; supplementary material, Figure S4 ). Importantly, this NBC-enriched cluster was also significantly enriched for TD-NBCs (29/53, 55%, p = 0.01, Fisher's exact test; Figure 6 ), suggesting that TD-NBCs show a repertoire of somatic mutations similar to that of histologically defined NBCs. It is of note that the same cluster was also significantly enriched for mucinous carcinomas (6/7, 87%, p = 0.044, Fisher's exact test; Figure 6 ). Consistent with the results of the comparisons between NBCs and common forms of ER + /HER2 − carcinomas (Figure 4 ), when the mutational repertoires of carcinomas from the NBC-enriched cluster were compared with those of the remaining ER + /HER2 − breast carcinomas from TCGA, PIK3CA, TP53, ARID1A, FOXA1 and SPEN were found to be mutated at significantly different frequencies (all p-values <0.05, Fisher's exact tests; Table 5 ).
Discussion
Here, we have demonstrated that NBCs harbour a repertoire of somatic mutations distinct from that of common types of ER + /HER2 − breast carcinoma, and that the constellation of somatic mutations in NBCs appears to be intermediate between that reported for PAM50-defined luminal A and luminal B breast carcinomas from TCGA. Furthermore, our study provides yet another line of evidence demonstrating that breast carcinomas with neuroendocrine differentiation comprise a rather heterogeneous group of invasive breast carcinomas.
Whether NBCs constitute a special histological type of breast carcinoma remains a matter of controversy. Although evidence of neuroendocrine differentiation in breast carcinomas has been investigated and acknowledged for decades, there is little consensus on its clinical and biological significance [18] . Part of this uncertainty stems from differing definitions of what constitutes an NBC, leading to inconsistencies in the classification of NBCs [18] . In this study, we investigated a cohort of invasive breast carcinomas showing both neuroendocrine morphological features and chromogranin A and/or synaptophysin expression in >50% of tumour cells, which were further classified according to the recognizable histological subtype, as previously recommended [18] . The genetic profiles of the two mucinous carcinomas and one lobular carcinoma with neuroendocrine differentiation analysed here were consistent with those expected for their histological subtypes, regardless of neuroendocrine differentiation. Indeed, akin to mucinous carcinomas, which have been shown to lack concurrent 1q gains and 16q losses [32, 36] and PIK3CA somatic mutations [37] , the two mucinous NBCs did not harbour these genetic alterations. In addition, the lobular NBC harboured a CDH1 mutation and concurrent 1q gain and 16q loss, akin to classic ILCs [16, 33] . Our data therefore support the current WHO recommendation of typing invasive carcinomas according to their special cytological and architectural features rather than the presence of neuroendocrine differentiation [8, 18] .
Despite the histological heterogeneity of NBCs, our sufficiently distinctive to prompt an investigation of neuroendocrine differentiation. This subset of NBCs harboured a relatively simple constellation of copy number alterations and a low prevalence of concurrent 1q gain and 16q losses, lacked TP53 mutations, and less frequently harboured PIK3CA mutations than common forms of ER + /HER2 − and PAM50-defined luminal A breast carcinomas. Notably, these genomic data highlight the genetic similarities between IDCs with neuroendocrine differentiation and mucinous carcinomas.
These observations are further supported by the comparison of the repertoire of somatic genetic alterations found in NBCs with that of mucinous carcinomas from the METABRIC study [38, 39] (supplementary material, Figures S5 and S6 ). Taken together, these results are consistent with the data of our previous transcriptomic analysis demonstrating that NBCs and mucinous carcinomas are transcriptionally distinct from IC-NSTs, and that NBCs and type B mucinous carcinomas have similar transcriptomic profiles [9] . 
Interestingly, our genomic data also suggest some similarities between NBCs and ILCs. Although evidence of an association between lobular carcinomas and neuroendocrine differentiation has been previously reported [3, 40, 41] , here we provide the novel observation that some somatic genetic alterations are shared by NBCs and lobular carcinomas. Indeed, NBCs were enriched for mutations affecting the transcription factor-encoding genes FOXA1 and TBX3, which have been reported to be more frequently mutated in lobular than in ductal carcinomas of no special type [16] . Although one of the CDH1 mutations found in the NBCs analysed here was found in an ILC with neuroendocrine differentiation, the TBX3 and FOXA1 somatic mutations were detected in NBCs of subtypes other than ILC.
We also investigated whether NBCs showed a distinct pattern of E-cadherin expression. Reduced E-cadherin expression was observed not only in the ILC, but also in 33% of the NBCs analysed, some of which showed negative areas at the front of invasion. Neuroendocrine tumours (NETs) of the gastrointestinal tract have been reported to lack E-cadherin expression [42] , whereas reduced E-cadherin expression has been reported in a prostate adenocarcinoma with neuroendocrine differentiation [43] . In addition, reduced E-cadherin expression has been observed in mucinous carcinomas of the breast associated with foci of lobular intraepithelial neoplasia [44] . Further studies to define the mechanisms of reduced E-cadherin expression in NETs are warranted.
NBCs, although showing some similarities in their repertoire of somatic genetic alterations with mucinous and lobular carcinomas, were also found to share some recurrently mutated genes with NETs of other anatomical sites. Interestingly, NETs harbour recurrent mutations affecting chromatin-remodelling genes, such as ARID1A (17% in NBCs and 6.8% in lung carcinoids) [31] and ATRX (5% in NBCs and 40% in pancreatic NETs) [45] . Furthermore, the lack of TP53 mutations in the NBCs analysed here is consistent with previous observations in regard to the prevalence of TP53 mutations in non-small cell neuroendocrine carcinomas from other anatomical sites [31, 46] . Further studies to dissect similarities and differences in the repertoire of somatic mutations in NBCs and NETs from other anatomical sites employing more comprehensive sequencing methods (e.g. whole-exome sequencing and whole-genome sequencing) are warranted.
This study has several limitations, including the small sample size, which precluded subgroup analyses between IDCs with neuroendocrine differentiation and special histological types showing neuroendocrine differentiation. It should be noted, however, that NBCs are rather rare. Second, the exploratory, hypothesis-generating analyses comparing NBCs stratified according to 'intrinsic' gene subtypes were performed with an immunohistochemical surrogate for the classification of NBCs, whereas TCGA samples were classified by the use of PAM50. Importantly, however, the differences observed remained significant even when NBCs were compared with ER + /HER2 − breast carcinomas from TCGA. Third, the lack of follow-up information precluded comparisons between the genomic findings and the outcome of NBC patients. Fourth, the definitions of the TD-NBCs and NBCs are not interchangeable, and the former constitutes only an approximation of the latter. In addition, the repertoire of somatic mutations found in TD-NBCs appears to be more heterogeneous than that of NBCs defined on the basis of morphology and immunohistochemically assessed expression of neuroendocrine markers. Despite these limitations, carcinomas included in the 'NBC-enriched cluster' were found to differ from the remaining ER + /HER2 − breast carcinomas on the basis of mutations affecting PIK3CA, TP53, ARID1A, and FOXA1, consistent with the results obtained through the analysis of NBCs. Finally, this study did not result in the identification of a pathognomonic or highly recurrent genetic alteration in NBCs. It should be noted, however, that we employed a targeted capture sequencing approach with baits targeting all coding regions of 254 genes that are recurrently mutated in breast carcinoma and/or related to DNA repair. It is plausible that more comprehensive analyses of NBCs with whole-genome, whole-exome and RNA-sequencing approaches may reveal somatic genetic alterations that define neuroendocrine differentiation. Importantly, however, whole-exome analyses of NETs from other sites failed to reveal pathognomonic mutations in those carcinomas [31, 45, 47, 48] .
In conclusion, we demonstrate here that NBCs constitute a heterogeneous group of carcinomas that, as a group, differ from common forms of ER + /HER2 − breast carcinomas on the basis of their lack of TP53 mutations, low frequency of PIK3CA mutations (similar to mucinous carcinomas), and enrichment of FOXA1 and TBX3 mutations (similar to lobular carcinomas). Akin [28] , and Lawrence et al [29] ) are shown. Non-synonymous somatic mutations are ordered from top to bottom in decreasing order of mutational frequency in carcinomas of the 'NBC-enriched cluster'.
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